Cargando…

Patient-reported outcomes among people living with HIV on single- versus multi-tablet regimens: Data from a real-life setting

BACKGROUND: The use of single-tablet regimens (STRs) in HIV treatment is ubiquitous. However, reintroducing the (generic) components as multi-tablet regimens (MTRs) could be an interesting cost-reducing strategy. It is essential to involve patient-reported outcome measures (PROs) to examine the effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Degroote, Sophie, Vandekerckhove, Linos, Vogelaers, Dirk, Vanden Bulcke, Charlotte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758085/
https://www.ncbi.nlm.nih.gov/pubmed/35025957
http://dx.doi.org/10.1371/journal.pone.0262533
_version_ 1784632826229948416
author Degroote, Sophie
Vandekerckhove, Linos
Vogelaers, Dirk
Vanden Bulcke, Charlotte
author_facet Degroote, Sophie
Vandekerckhove, Linos
Vogelaers, Dirk
Vanden Bulcke, Charlotte
author_sort Degroote, Sophie
collection PubMed
description BACKGROUND: The use of single-tablet regimens (STRs) in HIV treatment is ubiquitous. However, reintroducing the (generic) components as multi-tablet regimens (MTRs) could be an interesting cost-reducing strategy. It is essential to involve patient-reported outcome measures (PROs) to examine the effects of such an approach. Hence, this study compared PROs of people living with HIV taking an STR versus a MTR in a real world setting. MATERIALS AND METHODS: This longitudinal study included 188 people living with HIV. 132 remained on a MTR and 56 switched to an STR. At baseline, months 1-3-6-12-18 and 24, participants filled in questionnaires on health-related quality of life (HRQoL), depressive symptoms, HIV symptoms, neurocognitive complaints (NCC), treatment satisfaction and adherence. Generalized linear mixed models and generalized estimation equations mixed models were built. RESULTS: Clinical parameters and PROs of the two groups were comparable at baseline. Neurocognitive complaints and treatment satisfaction did differ over time among the groups. In the STR-group, the odds of having NCC increased monthly by 4,1% as compared to the MTR-group (p = 0.035). Moreover, people taking an STR were more satisfied with their treatment after 6 months: the median change score was high: 24 (IQR 7,5–29). Further, treatment satisfaction showed a contrary evolution in the groups: the estimated state score of the STR-group increased by 3,3 while it decreased by 0,2 in the MTR-group (p = 0.003). No differences over time between the groups were observed with regard to HRQoL, HIV symptoms, depressive symptoms and adherence. CONCLUSIONS: Neurocognitive complaints were more frequently reported among people on an STR versus MTR. This finding contrasts with the higher treatment satisfaction in the STR-group over time. The long-term effects of both PROs should guide the decision-making on STRs vs. (generic) MTRs.
format Online
Article
Text
id pubmed-8758085
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-87580852022-01-14 Patient-reported outcomes among people living with HIV on single- versus multi-tablet regimens: Data from a real-life setting Degroote, Sophie Vandekerckhove, Linos Vogelaers, Dirk Vanden Bulcke, Charlotte PLoS One Research Article BACKGROUND: The use of single-tablet regimens (STRs) in HIV treatment is ubiquitous. However, reintroducing the (generic) components as multi-tablet regimens (MTRs) could be an interesting cost-reducing strategy. It is essential to involve patient-reported outcome measures (PROs) to examine the effects of such an approach. Hence, this study compared PROs of people living with HIV taking an STR versus a MTR in a real world setting. MATERIALS AND METHODS: This longitudinal study included 188 people living with HIV. 132 remained on a MTR and 56 switched to an STR. At baseline, months 1-3-6-12-18 and 24, participants filled in questionnaires on health-related quality of life (HRQoL), depressive symptoms, HIV symptoms, neurocognitive complaints (NCC), treatment satisfaction and adherence. Generalized linear mixed models and generalized estimation equations mixed models were built. RESULTS: Clinical parameters and PROs of the two groups were comparable at baseline. Neurocognitive complaints and treatment satisfaction did differ over time among the groups. In the STR-group, the odds of having NCC increased monthly by 4,1% as compared to the MTR-group (p = 0.035). Moreover, people taking an STR were more satisfied with their treatment after 6 months: the median change score was high: 24 (IQR 7,5–29). Further, treatment satisfaction showed a contrary evolution in the groups: the estimated state score of the STR-group increased by 3,3 while it decreased by 0,2 in the MTR-group (p = 0.003). No differences over time between the groups were observed with regard to HRQoL, HIV symptoms, depressive symptoms and adherence. CONCLUSIONS: Neurocognitive complaints were more frequently reported among people on an STR versus MTR. This finding contrasts with the higher treatment satisfaction in the STR-group over time. The long-term effects of both PROs should guide the decision-making on STRs vs. (generic) MTRs. Public Library of Science 2022-01-13 /pmc/articles/PMC8758085/ /pubmed/35025957 http://dx.doi.org/10.1371/journal.pone.0262533 Text en © 2022 Degroote et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Degroote, Sophie
Vandekerckhove, Linos
Vogelaers, Dirk
Vanden Bulcke, Charlotte
Patient-reported outcomes among people living with HIV on single- versus multi-tablet regimens: Data from a real-life setting
title Patient-reported outcomes among people living with HIV on single- versus multi-tablet regimens: Data from a real-life setting
title_full Patient-reported outcomes among people living with HIV on single- versus multi-tablet regimens: Data from a real-life setting
title_fullStr Patient-reported outcomes among people living with HIV on single- versus multi-tablet regimens: Data from a real-life setting
title_full_unstemmed Patient-reported outcomes among people living with HIV on single- versus multi-tablet regimens: Data from a real-life setting
title_short Patient-reported outcomes among people living with HIV on single- versus multi-tablet regimens: Data from a real-life setting
title_sort patient-reported outcomes among people living with hiv on single- versus multi-tablet regimens: data from a real-life setting
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758085/
https://www.ncbi.nlm.nih.gov/pubmed/35025957
http://dx.doi.org/10.1371/journal.pone.0262533
work_keys_str_mv AT degrootesophie patientreportedoutcomesamongpeoplelivingwithhivonsingleversusmultitabletregimensdatafromareallifesetting
AT vandekerckhovelinos patientreportedoutcomesamongpeoplelivingwithhivonsingleversusmultitabletregimensdatafromareallifesetting
AT vogelaersdirk patientreportedoutcomesamongpeoplelivingwithhivonsingleversusmultitabletregimensdatafromareallifesetting
AT vandenbulckecharlotte patientreportedoutcomesamongpeoplelivingwithhivonsingleversusmultitabletregimensdatafromareallifesetting